Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 3/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9316725 | 0.77 | — | — | |
| SCHEMBL20969063 | 0.77 | LMNA (0.40) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL8369782 | 0.75 | — | — | |
| SCHEMBL2724120 | 0.74 | SMN1; SMN2 (0.38) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL88209 | 0.73 | CYP1A2 (0.44) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL3713828 | 0.73 | CYP1A2 (0.44) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL15047670 | 0.73 | CYP1A2 (0.40) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL2179403 | 0.72 | — | — | |
| SCHEMBL11370542 | 0.72 | — | — | |
| SCHEMBL28185763 | 0.71 | AKR1B1 (0.41) | BBOX1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2413901-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | Cerulean Pharma Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011119995-A2 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2011063421-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | TET2 4261/4885KDM4A 4562/4885KDM4C 4128/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | TET2 4261/4885KDM4A 4562/4885KDM4C 4128/4885 |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | TET2 3637/4885KDM4A 4278/4885KDM4C 3911/4885 |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | TET2 3637/4885KDM4A 4278/4885KDM4C 3911/4885 |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | LPXN, LIPA, CHMP4B | TET2 2351/4885KDM4A 3624/4885KDM4C 2877/4885 |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | TET2 3637/4885KDM4A 4278/4885KDM4C 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.